GET DAILY SIGNALSTuHURA Biosciences (HURA): Clinical Responses and Patent News Shape the Outlook
Key Takeaways
- TuHURA Biosciences (HURA) has traded roughly flat over the trailing month, ending near $2.11 after a sharp late-October rally.
- Preliminary data from its open-label IFx-2.0 study showed confirmed tumor responses in the first patients with metastatic Merkel cell carcinoma.
- The U.S. Patent and Trademark Office issued a new patent broadening coverage for the company's VISTA inhibitor, TBS-2025.
- The company remains pre-revenue and clinical-stage, with an analyst consensus rating of "Buy" and an average 12-month price target near $8.04.
- HURA is a high-volatility micro-cap, with a 52-week trading range of roughly $0.41 to $3.43.
- For deeper data on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- Investors seeking systematic strategies can also explore Trending AI Robots.
HURA's Recent Price Action and Market Position
TuHURA Biosciences (HURA) closed the most recent session near $2.11, up about 3.4% on the day. Over the trailing 30 days the stock has been essentially flat, though that headline obscures significant intra-period volatility: shares slid below $1.80 in mid-October before rebounding sharply following a clinical data update and new patent issuance. With a market capitalization of roughly $134 million and no product revenue to date, HURA trades more like a binary biotech asset than a steady-growth equity, and its weekly price swings have been substantially wider than the broader market.
Sentiment is concentrated around a small group of covering analysts, who currently hold a consensus "Buy" rating with a 12-month average target near $8.04. The wide gap between the current price and that target reflects both the early-stage nature of the pipeline and the high uncertainty embedded in clinical development. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Understanding TuHURA Biosciences' Focus and Pipeline
TuHURA Biosciences is a clinical-stage immuno-oncology company headquartered in Tampa, Florida, focused on overcoming primary and acquired resistance to cancer immunotherapies. Its lead candidate, IFx-2.0, is an innate immune agonist designed to make tumor cells resemble bacteria so the body's own immune system attacks them, and it is being studied as an adjunctive therapy to checkpoint inhibitors such as Keytruda.
The pipeline also includes a Delta receptor technology platform aimed at developing tumor microenvironment modulators, including bi-functional and bi-specific antibody-drug conjugates that target myeloid-derived suppressor cells, as well as the mRNA-based candidate IFx-3.0 for blood-related cancers and the VISTA inhibitor TBS-2025. Investors follow the stock primarily for clinical readouts and regulatory milestones, since the company has yet to generate product revenue.
Key Catalysts: Clinical Data and Patent Grant
The most significant recent catalyst was the initial data from TuHURA's open-label study of IFx-2.0 in the first-line treatment of patients with deep-seated metastatic Merkel cell carcinoma. The company reported that the first three treated patients achieved confirmed objective responses sustained through week 24, with no serious adverse events reported across the four patients treated so far. The 9-to-12-patient study is intended to inform feasibility, safety, and potential discussions with the FDA.
Separately, the U.S. Patent and Trademark Office issued a new patent that broadens coverage for TBS-2025, the company's VISTA-inhibiting antibody, extending it to include bispecific and multi-specific antibodies across classes of human antibodies. These announcements contributed to a pronounced volume spike and price rebound in late October, though the stock has not yet sustained a breakout beyond its recent range. From what I see, these milestones are worth monitoring closely for any follow-through.
2026 Outlook and What Investors Should Watch
Looking ahead, the key events for HURA center on clinical execution and data catalysts. Investors will monitor further results from the IFx-2.0 Merkel cell carcinoma study, including durability of responses and safety across additional patients, as well as any progress toward FDA discussions and the planned Phase 3 registration trial. Additional milestones could include development updates on the Delta receptor antibody-drug conjugate platform, IFx-3.0, and the VISTA inhibitor TBS-2025.
On the financial side, the company's quarterly results, with an estimated earnings report in mid-November 2026, will be watched for cash runway, operating-expense trends, and any financing activity, given that TuHURA remains pre-revenue. As a clinical-stage micro-cap, HURA is also sensitive to broader biotechnology financing conditions and risk sentiment. These factors, rather than near-term revenue, will likely shape the stock's trajectory.
How I Use Tickeron’s AI Tools for Research
In my own work, I turn to Tickeron’s AI Trading Bots to test systematic approaches on volatile names like this one. The platform lets me review performance metrics across different strategies and timeframes, which helps put clinical-stage biotech moves into a broader, data-driven context without replacing fundamental analysis. It is one more layer I find useful when weighing entry points or position sizing.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HURA in upward trend: price rose above 50-day moving average on October 23, 2026
HURA moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend. In 39 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HURA's RSI Indicator exited the oversold zone, 31 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on HURA as a result. In 75 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for HURA just turned positive on October 21, 2026. Looking at past instances where HURA's MACD turned positive, the stock continued to rise in 32 of 42 cases over the following month. The odds of a continued upward trend are 76%.
Following a +5.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where HURA advanced for three days, in 180 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
HURA broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HURA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. HURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.379) is normal, around the industry mean (2.974). P/E Ratio (-3.907) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement